Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARAV

ARAV - Aravive Inc Stock Price, Fair Value and News

0.04USD Market Closed
Watchlist

Market Summary

USD0.04
Market Closed

ARAV Stock Price

View Fullscreen

ARAV RSI Chart

ARAV Valuation

Market Cap

2.9M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

0.42

EV/EBITDA

0.03

Price/Free Cashflow

-0.05

ARAV Price/Sales (Trailing)

ARAV Profitability

EBT Margin

-1091.25%

Return on Equity

-2.3K%

Return on Assets

-305.36%

Free Cashflow Yield

-2.0K%

ARAV Fundamentals

ARAV Revenue

Revenue (TTM)

7.0M

Rev. Growth (Yr)

-44.39%

Rev. Growth (Qtr)

116.33%

ARAV Earnings

Earnings (TTM)

-39.8M

Earnings Growth (Yr)

235.52%

Earnings Growth (Qtr)

17.87%

Breaking Down ARAV Revenue

Last 30 days

-66.7%

Last 90 days

-71.4%

Trailing 12 Months

-97.6%

How does ARAV drawdown profile look like?

ARAV Financial Health

Current Ratio

0.98

ARAV Investor Care

Shares Dilution (1Y)

22.96%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20239.5M9.2M7.0M0
20228.3M6.1M8.6M9.1M
20216.1M6.6M7.0M7.4M
20205.0M5.2M5.5M5.7M
20190004.8M
20180000
201700040.0M

Tracking the Latest Insider Buys and Sells of Aravive Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 24, 2022
zhang eric
acquired
500,000
0.9199
543,537
-
Oct 24, 2022
ho peter tai-ching
acquired
49,999
0.9199
54,353
-
Oct 24, 2022
giaccia amato
acquired
249,999
0.9199
271,768
-
Oct 24, 2022
mcintyre gail frances
acquired
49,999
0.9199
54,353
ceo and president
Oct 24, 2022
howard rudy
acquired
9,999
0.9199
10,870
chief financial officer
Oct 24, 2022
eshelman fredric n
acquired
15,000,000
0.9199
16,306,100
executive chairman
Apr 01, 2022
eshelman fredric n
acquired
454
0.0001
4,545,460
executive chairman of board
Mar 29, 2022
eshelman fredric n
acquired
2,000,000
2.325
860,216
executive chairman of board

1–10 of 29

Which funds bought or sold ARAV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 26, 2024
Virtu Financial LLC
reduced
-58.25
-7,000
5,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
245,000
245,000
0.02%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
1,596
1,596
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
unchanged
-
-3.00
43.00
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-14.56
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
reduced
-3.93
-15,000
135,414
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-52,245
-
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-38.84
-2,340
3,144
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
reduced
-40.88
-16,634
20,663
-%

1–10 of 40

Are Funds Buying or Selling ARAV?

Are funds buying ARAV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARAV
No. of Funds

Unveiling Aravive Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
biotechnology value fund l p
7.1%
5,664,238
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
4.99%
3,863,568
SC 13G/A
Feb 09, 2024
artal international s.c.a.
9.4%
7,609,522
SC 13G/A
Feb 14, 2023
baker bros. advisors lp
7.5%
4,586,404
SC 13G
Feb 13, 2023
artal international s.c.a.
9.9%
12,182,037
SC 13G/A
Dec 28, 2022
zhang eric
3.4%
2,029,634
SC 13D/A
Dec 27, 2022
giaccia amato
2.9%
1,725,244
SC 13D/A
Nov 07, 2022
biotechnology value fund l p
6.4%
3,908,320
SC 13G
Nov 03, 2022
eshelman ventures, llc
43.5%
26,378,105
SC 13D/A
Apr 05, 2022
eshelman fredric n
33.9%
10,071,985
SC 13D/A

Recent SEC filings of Aravive Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
15-12G
15-12G
Feb 01, 2024
EFFECT
EFFECT
Feb 01, 2024
EFFECT
EFFECT
Feb 01, 2024
EFFECT
EFFECT
Feb 01, 2024
EFFECT
EFFECT
Feb 01, 2024
EFFECT
EFFECT
Jan 29, 2024
POS AM
POS AM

Peers (Alternatives to Aravive Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.9B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.69
7.12
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.3B
396.6M
-2.06% 34.31%
-15.62
20.82
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.59
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
4.1B
726.4M
-12.60% 32.37%
-66.62
5.62
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
SMALL-CAP
1.7B
398.2M
-3.38% -9.50%
23.17
4.16
85.90% -14.05%
740.4M
983.7M
-9.17% -57.89%
-1.36
0.75
-50.36% 17.16%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aravive Inc News

Latest updates
InvestorPlace18 Jan 202408:00 am
Yahoo Finance17 Jan 202408:00 am
InvestorPlace7 months ago

Aravive Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue116.3%2,756,0001,274,0001,491,0001,474,0004,956,0001,615,0001,092,000985,0002,412,0003,789,0003,157,5002,526,0001,894,5001,263,000631,500--3,054,0001,699,0009,359,20017,019,400
Operating Expenses-15.8%11,670,00013,860,00019,404,00021,338,00021,504,00021,042,00016,090,00014,641,50013,986,00011,200,0008,264,0009,734,50010,699,0005,723,00010,312,0005,163,0006,998,0006,928,0007,438,00052,607,0006,218,000
  S&GA Expenses-4.2%2,940,0003,070,0003,489,0003,385,0002,836,0003,727,0003,088,0002,447,5002,643,0003,080,0002,380,0003,198,5002,715,0003,201,0003,951,0002,652,0003,158,0003,291,0004,590,00011,284,0005,191,000
  R&D Expenses-------------5,070,0002,522,0003,491,000-3,840,0003,637,0002,848,0003,010,0001,027,000
EBITDA Margin-31.4%-10.44-7.94-7.66-7.99-8.44-11.96-8.81-9.80-10.41-11.08-11.75-12.68---------
Earnings Before Taxes---------------------50,954,000-6,550,000
EBT Margin-31.5%-10.91-8.30-8.00-8.35-8.83-12.51-9.22-10.26-10.90-11.63-12.46-13.43---------
Net Income17.9%21,226,00018,008,000-49,956,000-29,125,000-15,663,000-18,477,000-13,057,000-12,956,000-11,086,000-7,105,000-8,004,000-4,046,000-10,660,000-5,041,000-10,796,000-4,328,000-6,142,000-3,044,000-4,704,000-50,954,000-6,550,000
Net Income Margin31.7%-5.70-8.35-11.87-8.35-6.96-9.10-5.34-5.26-4.32-4.54-4.53-5.37-5.65--------
Free Cashflow34.0%-9,808,000-14,869,000-14,965,000-11,449,000-16,145,000-16,234,000-10,103,000-5,556,000-5,876,000-2,365,000-7,232,0007,011,000-3,510,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-49.3%13.0026.0043.0062.0042.0056.0074.0068.0077.0085.0087.0068.0061.0071.0072.0082.0063.0067.0072.0069.0074.00
  Current Assets-56.6%10.0022.0039.0058.0038.0051.0069.0063.0072.0080.0081.0062.0055.0061.0061.0068.0048.0052.0057.0058.0063.00
    Cash Equivalents-53.5%9.0018.0036.0054.0028.0047.0066.0059.0068.0075.0079.0061.0054.0060.0063.0068.0047.0051.0058.0059.0065.00
  Net PPE-18.1%0.000.000.000.000.000.000.000.000.000.001.001.001.001.001.002.002.002.002.000.00-
Liabilities-75.1%11.0046.0082.0051.0027.0026.0035.0026.0022.0021.0019.0020.0012.0012.0013.0013.0015.0014.0017.0010.0010.00
  Current Liabilities-31.2%10.0014.0020.0022.0024.0021.0020.0018.0014.0012.009.009.005.005.005.005.006.005.007.002.003.00
Shareholder's Equity-99.7%2.0062862711.0015.0030.0039.0042.0054.0064.0069.0048.0049.0059.0059.0069.0048.0053.0055.0060.0064.00
  Retained Earnings3.3%-626-648-666-616-587-571-552-539-526-515-508-500-496-485-480-470-465-459-4561.00-399
  Additional Paid-In Capital0.0%629628627627602601592582581580577549546545540539513513512511463
Shares Outstanding22.9%74.0060.0060.0060.0031.0031.0024.0021.0021.0021.0020.0016.00---------
Float------19.00---89.00---141---45.00---
Cashflow (Last 12 Months)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations44.4%-9,808-17,656-17,752-14,236-18,932-19,021-12,890-8,343-8,663-5,152-10,0194,224-6,297-5,634-4,462-5,072-3,401-7,212-1,396-8,777-5,184
  Share Based Compensation-61.6%2927616885766397256205856275405053853764887176108009411,0489,8501,313
Cashflow From Investing--------------------1,272-
Cashflow From Financing-100.0%-25.00-40,049-29.0019,2912577371,90728,1602,3502034,99733.0025,2361.00---17.00

ARAV Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue    
Total revenue$ 2,756$ 4,956$ 5,520$ 7,663
Operating expenses    
Research and development8,73018,66835,43548,985
General and administrative2,9402,8369,4999,651
Total operating expenses11,67021,50444,93458,636
Loss from operations(8,914)(16,548)(39,414)(50,973)
Other income (expense), net:    
Interest income2091471,028220
Change in fair value of warrant liability29,231025,6161,410
Other income, net7007382,0482,146
Total other income (expense), net30,14088528,6923,776
Net income (loss)$ 21,226$ (15,663)$ (10,722)$ (47,197)
Net income (loss) per share    
Basic (in dollars per share)$ 0.28$ (0.51)$ (0.14)$ (1.72)
Diluted (in dollars per share)$ 0.28$ (0.51)$ (0.38)$ (1.72)
Weighted-average shares used to compute net income (loss) per share    
Basic (in shares)75,73930,51875,72727,419
Diluted (in shares)76,09330,51895,44127,419
Collaborative Arrangement [Member]    
Revenue    
Total revenue$ 2,756$ 4,956$ 5,520$ 7,663

ARAV Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 8,535$ 53,689
Prepaid expenses and other current assets1,0274,281
Total current assets9,56257,970
Restricted cash2,4082,445
Property and equipment, net167270
Operating lease right-of-use assets9071,462
Other assets56
Total assets13,04962,153
Current liabilities  
Accounts payable5,4238,765
Accrued liabilities2,2336,738
Operating lease obligation, current portion2,1212,195
Current portion of deferred revenue04,414
Total current liabilities9,77722,112
Deferred revenue, net of current portion0621
Operating lease obligation, net of current portion3061,882
Warrant liability1,26526,881
Total liabilities11,34851,496
Commitments and contingencies (Note 6)
Stockholders' equity  
Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2023 and 100,000,000 shares authorized at December 31, 2022; 73,562,648 shares issued and outstanding at September 30, 2023 and 59,844,850 shares issued and outstanding at December 31, 202276
Additional paid-in capital628,543626,778
Accumulated deficit(626,849)(616,127)
Total stockholders' equity1,70110,657
Total liabilities and stockholders’ equity$ 13,049$ 62,153
ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
 CEO
 WEBSITEaravive.com
 EMPLOYEES23

Aravive Inc Frequently Asked Questions


What is the ticker symbol for Aravive Inc? What does ARAV stand for in stocks?

ARAV is the stock ticker symbol of Aravive Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aravive Inc (ARAV)?

As of Wed Feb 07 2024, market cap of Aravive Inc is 2.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARAV stock?

You can check ARAV's fair value in chart for subscribers.

What is the fair value of ARAV stock?

You can check ARAV's fair value in chart for subscribers. The fair value of Aravive Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aravive Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARAV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aravive Inc a good stock to buy?

The fair value guage provides a quick view whether ARAV is over valued or under valued. Whether Aravive Inc is cheap or expensive depends on the assumptions which impact Aravive Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARAV.

What is Aravive Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 07 2024, ARAV's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 0.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARAV PE ratio will change depending on the future growth rate expectations of investors.